Secondary objectives are (i) to evaluate the impact of ATT on secondary outcomes such as psychiatric disorders, rumination, worry, type D-personality, insomnia, quality of life and metacognitions (ii) explore whether the biological marker CRP that may link psychological factors to cardiac prognosis is correlated with treatment outcome, and (iii) provide qualitative data on the patients experience with ATT including processes that may facilitate or serve as barriers to effectiveness in order to help further improvement in effective delivery and implementation of ATT in cardiac practice. The gene discussed is CRP; the disease is insomnia measurement.